Skip to content

A historical control study of the efficiency of bumetanide on children with Autism Spectrum Disorder

A historical control study of the efficiency of bumetanide on children with Autism Spectrum Disorder

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPC-16008336
Enrollment
Unknown
Registered
2016-04-21
Start date
2016-04-21
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Interventions

Group A:before treatment
Group B:bumetanide

Sponsors

Shanghai Children's Medical Center,Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The patients, aged from 3 to 12 years old, were given the diagnosis of ASD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) , by a team of autism experts; Scores for Children Autism Rating Scale (CARS) were more than 30; Signed Informed Consents were provided by parents.

Exclusion criteria

Exclusion criteria: Liver and kidney dysfunction; With a history of allergy to sulfa drugs; abnormal ECG; chromosomal abnormality; suffering from nervous system diseases (such as epilepsy, schizophrenia, and so on); using the melatonin treatment for sleep disorders or withdrawal less than three weeks

Design outcomes

Primary

MeasureTime frame
ADOS score;CARS score;ADI-R score;GESELL score;CGI score;imaging score;

Countries

China

Contacts

Public ContactFei Li

Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine

feili@shsmu.edu.cn+86 18930830950

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026